Carboplatin is commonly used for treating many solid cancers, but many patients develop resistance, necessitating combination treatment. Preclinical studies have shown that the combination of ceralasertib, an ATR inhibitor, and carboplatin may hold clinical promise. Here, Yap and colleagues report the results of a multicenter phase I study of ceralasertib plus carboplatin in patients with advanced solid cancers. This combination was well tolerated and showed potential clinical activity, with 18 of 34 patients showing stable disease. Two patients with absent or low ATM or SLFN11 protein expression achieved confirmed partial responses. Further clinical study is necessary to validate the clinical utility of this combination.

The randomized phase III coBRIM study (NCT01689519) demonstrated that the addition of cobimetinib to vemurafenib improved progression-free survival (PFS) and overall survival (OS) in patients with previously untreated BRAFV600-positive advanced melanoma. Ascierto and colleagues report long-term follow-up of this study. Over at least 5 years of...

You do not currently have access to this content.